Although the transfection of FLT3 expression constructs in T-ALL cell lines remains an in vitro system, the distinct sensitivity to TKIs together with the positive experience in AML support the rational for the clinical use of TKIs in FLT3mut ETP-ALL. Here, FLT3 is linked to acute lymphoblastic leukemia.